Compare · BLTE vs JNJ
BLTE vs JNJ
Side-by-side comparison of Belite Bio Inc (BLTE) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BLTE and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $574.10B, about 106.8x BLTE ($5.37B).
- Over the past year, BLTE is up 124.5% and JNJ is up 54.6% - BLTE leads by 69.9 points.
- JNJ has been more active in the news (11 items in the past 4 weeks vs 4 for BLTE).
- JNJ has more recent analyst coverage (25 ratings vs 9 for BLTE).
- Company
- Belite Bio Inc
- Johnson & Johnson
- Price
- $137.59+0.47%
- $239.99+0.61%
- Market cap
- $5.37B
- $574.10B
- 1M return
- -12.03%
- +6.97%
- 1Y return
- +124.45%
- +54.60%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- News (4w)
- 4
- 11
- Recent ratings
- 9
- 25
Belite Bio Inc
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest BLTE
- Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
- SEC Form 6-K filed by Belite Bio Inc
- Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update
- Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland
- Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)
- Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results
- Chief Scientific Officer Mata Nathan L. sold $102,039 worth of American depositary share (666 units at $153.21) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)
- Chief Scientific Officer Mata Nathan L. sold $153,839 worth of American depositary share (1,000 units at $153.84) as part of a pre-agreed trading plan, decreasing direct ownership by 60% to 666 units (SEC Form 4)
- Chief Scientific Officer Mata Nathan L. sold $155,502 worth of American depositary share (1,000 units at $155.50) as part of a pre-agreed trading plan, decreasing direct ownership by 38% to 1,666 units (SEC Form 4)
- Chief Scientific Officer Mata Nathan L. sold $155,636 worth of American depositary share (1,000 units at $155.64) as part of a pre-agreed trading plan, decreasing direct ownership by 27% to 2,666 units (SEC Form 4)
Latest JNJ
- Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients
- IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies
- Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial
- Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
- Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
- Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
- New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
- FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
- Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results